These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28553566)

  • 1. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of FDA's Expanded Access Program for Investigational Drugs.
    Jarow JP; Lurie P; Ikenberry SC; Lemery S
    Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
    Jarow JP; Moscicki R
    Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies.
    Van Norman GA
    JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
    Van Norman GA
    JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases.
    Khan A; Bellio MA; Schulman IH; Levi AD; Longsomboon B; Brooks A; Valasaki K; DiFede DL; Pujol MV; Yavagal DR; Bates KE; Si MS; Kaushal S; Green BA; Anderson KD; Guest JD; Burks SS; Silvera R; Santamaria AJ; Lalwani A; Dietrich WD; Hare JM
    Front Cell Dev Biol; 2021; 9():675738. PubMed ID: 34169074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology.
    Shulman DS; Kiwinda LV; Edwards S; Clinton CM; Hunt S; Greenspan L; Lawler KD; Reaman G; Al-Sayegh H; Bona K; O'Neill AF; Shusterman S; Janeway KA; Place AE; Chi SN; Ma C; DuBois SG
    Cancer Med; 2021 Apr; 10(7):2310-2318. PubMed ID: 33751835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncology Expanded Access and FDA's Project Facilitate.
    Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
    Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
    Riner A; Chan-Tack KM; Murray JS
    Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017-2019.
    Poddar A; Raggio M; Concato J
    Ther Innov Regul Sci; 2024 Jan; 58(1):214-221. PubMed ID: 37926768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants.
    Chahal HS; Mukherjee S; Sigelman DW; Temple R
    JAMA Intern Med; 2021 Apr; 181(4):522-529. PubMed ID: 33587091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
    Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
    Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.